Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Left Atrial Isolation by Catheter Ablation in Persistent Atrial Fibrillation With Severe Atrial Fibrosis
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05173779
Augmented Reality-assisted Localization of Solitary Pulmonary Nodules for Precise Sublobar Lung Resection
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05162235
Catheter Ablation and Surgical Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05153486
Catgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05125042
Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05103501
Driver Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis.
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- Procedure: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablationProcedure: Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolationProcedure: Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05085912
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05078931
- Locations
- 🇨🇳
Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Cardiac Autonomic Nerve Improvement and Pacemaker Therapy in Patients With Sinus Bradycardia
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05021627
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05005468
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04985851
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath